Market closed

Enanta/$ENTA

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Enanta

Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.

Ticker

$ENTA
Trading on

Industry

Biotechnology

Employees

131

Enanta Metrics

BasicAdvanced
$124M
Market cap
-
P/E ratio
-$5.48
EPS
0.49
Beta
-
Dividend rate
$124M
0.49
$17.80
$5.70
379K
5.212
4.985
147.555
175.492
-11.12%
-18.13%
-67.17%
1.833
0.96
0.96
-1.282
-14.61%
-14.05%
-11.35%
11.88%

What the Analysts think about Enanta

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Enanta stock.

Enanta Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Enanta Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ENTA

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Enanta stock?

Enanta (ENTA) has a market cap of $124M as of December 21, 2024.

What is the P/E ratio for Enanta stock?

The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of December 21, 2024.

Does Enanta stock pay dividends?

No, Enanta (ENTA) stock does not pay dividends to its shareholders as of December 21, 2024.

When is the next Enanta dividend payment date?

Enanta (ENTA) stock does not pay dividends to its shareholders.

What is the beta indicator for Enanta?

Enanta (ENTA) has a beta rating of 0.49. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.